CN110237190A - A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine - Google Patents
A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine Download PDFInfo
- Publication number
- CN110237190A CN110237190A CN201910680778.4A CN201910680778A CN110237190A CN 110237190 A CN110237190 A CN 110237190A CN 201910680778 A CN201910680778 A CN 201910680778A CN 110237190 A CN110237190 A CN 110237190A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- traditional chinese
- chinese
- stein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 23
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract 9
- 229940079593 drug Drugs 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 36
- 238000002347 injection Methods 0.000 claims abstract description 21
- 239000007924 injection Substances 0.000 claims abstract description 21
- 230000016087 ovulation Effects 0.000 claims abstract description 15
- 230000006872 improvement Effects 0.000 claims abstract description 10
- 230000003750 conditioning effect Effects 0.000 claims abstract description 6
- 210000001672 ovary Anatomy 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 7
- 239000002398 materia medica Substances 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 10
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims description 9
- 241000830535 Ligustrum lucidum Species 0.000 claims description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 244000144730 Amygdalus persica Species 0.000 claims description 5
- 244000124853 Perilla frutescens Species 0.000 claims description 5
- 229960004539 alirocumab Drugs 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000006286 aqueous extract Substances 0.000 claims 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 2
- 239000003643 water by type Substances 0.000 claims 2
- 244000247747 Coptis groenlandica Species 0.000 claims 1
- 235000002991 Coptis groenlandica Nutrition 0.000 claims 1
- 240000004638 Dendrobium nobile Species 0.000 claims 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 235000004348 Perilla frutescens Nutrition 0.000 claims 1
- 241001499733 Plantago asiatica Species 0.000 claims 1
- 241000205407 Polygonum Species 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- 241001411234 Sagina subulata Species 0.000 claims 1
- 241000505722 Uraria Species 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 206010061623 Adverse drug reaction Diseases 0.000 abstract 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000019634 flavors Nutrition 0.000 description 12
- 210000003734 kidney Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 241000748223 Alisma Species 0.000 description 5
- 241000981770 Buddleja asiatica Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 241001523681 Dendrobium Species 0.000 description 5
- 235000003805 Musa ABB Group Nutrition 0.000 description 5
- 235000015266 Plantago major Nutrition 0.000 description 5
- 240000008790 Musa x paradisiaca Species 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 241000013557 Plantaginaceae Species 0.000 description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- 241000691803 Urobatis jamaicensis Species 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 3
- 244000292697 Polygonum aviculare Species 0.000 description 3
- 235000006386 Polygonum aviculare Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000010015 huanglian Substances 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000013017 Child Nutrition disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000006353 Filariasis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001375221 Micranthemum glomeratum Species 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000234295 Musa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明涉及制药治疗方法技术领域,具体是指一种改善多囊卵巢综合征中西医结合治疗方法。The invention relates to the technical field of pharmaceutical treatment methods, in particular to a treatment method for improving polycystic ovary syndrome with integrated traditional Chinese and western medicine.
背景技术Background technique
多囊卵巢综合征至今病因不明,病机复杂,病情顽固,病程长,复发率高,临床治疗颇为棘手。The etiology of polycystic ovary syndrome is unknown so far, the pathogenesis is complicated, the condition is stubborn, the course of disease is long, the recurrence rate is high, and the clinical treatment is quite difficult.
PCOS患者目前常用避孕药达英-35,不能恢复女性生理-排卵月经周期;与非PCOS患者相比,PCOS患者静脉血栓栓塞性疾病的基线风险增加1.5倍,使用达英-35的患者增加3.7倍;其次,达英-35用于青春期PCOS的治疗中,很大程度上会抑制女孩身高生长。而螺内酯及二甲双胍均没有调节月经的作用。对于月经稀发或闭经的患者,长期服用螺内酯易发生子宫内膜增生或子宫内膜癌。有报道称二甲双胍在中孕期应用可能增加围生期胎儿死亡率,同时服用二甲双胍有些患者会出现胃肠道反应,如腹泻、恶心、呕吐、腹胀及厌食等。药物和手术促排卵有局限性,治疗时才能产生排卵并不能恢复自主排卵且不能长期使用,克罗米芬(CC)、尿促性腺激素(HMG)、人绒毛膜促性腺激素(HCG)会引起多胎、卵巢过度刺激综合征(OHSS)。卵巢楔形切除术、腹腔镜下卵巢打孔术虽避免了多胎妊娠,流产率低,但存在腹腔镜手术常规风险、粘连、损伤正常卵巢组织等不利因素。体外受精—胚胎移植(IVF-ET)治疗过程中则具有获卵数多、受精率低、OHSS发生率高的特点。Diane-35, a commonly used contraceptive pill for PCOS patients, cannot restore the female physiological-ovulatory menstrual cycle; compared with non-PCOS patients, the baseline risk of venous thromboembolic disease in PCOS patients increased by 1.5 times, and that of patients using Diane-35 increased by 3.7 Second, Diane-35 used in the treatment of adolescent PCOS can largely inhibit the growth of girls' height. Both spironolactone and metformin have no effect on regulating menstruation. For patients with oligomenorrhea or amenorrhea, long-term use of spironolactone is prone to endometrial hyperplasia or endometrial cancer. It has been reported that the application of metformin in the second trimester may increase perinatal fetal mortality, and some patients who take metformin at the same time may experience gastrointestinal reactions, such as diarrhea, nausea, vomiting, abdominal distension and anorexia. Drugs and surgical ovulation induction have limitations. Ovulation can only be produced during treatment and spontaneous ovulation cannot be restored, and it cannot be used for a long time. Clomiphene (CC), urinary gonadotropin (HMG), and human chorionic gonadotropin (HCG) can cause multiple births , Ovarian hyperstimulation syndrome (OHSS). Although ovarian wedge resection and laparoscopic ovarian drilling can avoid multiple pregnancy and have a low miscarriage rate, there are disadvantages such as conventional laparoscopic surgery risks, adhesions, and damage to normal ovarian tissue. In vitro fertilization-embryo transfer (IVF-ET) has the characteristics of large number of retrieved eggs, low fertilization rate and high incidence of OHSS.
中医认为多囊卵巢综合征病机为肾、肝和脾脏功能失调,痰浊、瘀血留滞,多属本虚标实之证。中医治疗多囊卵巢综合征的核心是辨证论治,常见证型为脾肾阳虚、痰瘀互结、肾虚血瘀、肾阴虚。治法集中在补肾、活血化瘀和祛湿化痰,少数根据辨证采用疏肝、健脾法;用药集中在补肾阳药、活血化瘀药和温化痰湿药。但单纯中医药治疗在临床上往往难以解决因持续不排卵所导致的闭经及月经失调、高雄激素所导致的多毛、痤疮等,所以在临床上常采用“中药联合口服避孕药物”的治疗模式;由于难以达到自主排卵的作用,对有生育要求者常采用“中药联合西药促排卵药物”的治疗模式。因此通过中西医结合的治疗方式是更为科学有效的治疗方法。Traditional Chinese medicine believes that the pathogenesis of polycystic ovary syndrome is kidney, liver and spleen dysfunction, phlegm turbidity, and stagnant blood stagnation, which mostly belong to the syndrome of deficiency in the root and excess in the superficiality. The core of TCM treatment of polycystic ovary syndrome is syndrome differentiation and treatment. The common syndrome types are spleen and kidney yang deficiency, phlegm and blood stasis, kidney deficiency and blood stasis, and kidney yin deficiency. The treatment methods focus on tonifying the kidney, promoting blood circulation to remove blood stasis, and dispelling dampness and resolving phlegm. A few of them use the method of soothing the liver and invigorating the spleen according to syndrome differentiation; However, it is often difficult to solve the amenorrhea and menstrual disorders caused by continuous anovulation, hirsutism and acne caused by hyperandrogen in clinical practice, so the treatment mode of "Chinese medicine combined with oral contraceptives" is often used clinically; Because it is difficult to achieve the effect of spontaneous ovulation, the treatment mode of "Chinese medicine combined with Western medicine to induce ovulation" is often used for those who have fertility requirements. Therefore, the combination of traditional Chinese and Western medicine is a more scientific and effective treatment method.
发明内容Contents of the invention
本发明要解决的技术问题是,克服现有技术缺点,提供一种改善多囊卵巢综合征中西医结合治疗方法,中西药结合治疗,中药制剂主要用于患者机体基础调理,西药组合物主要用于促进患者机体卵巢排卵功能。The technical problem to be solved by the present invention is to overcome the shortcomings of the prior art and provide a method for improving the treatment of polycystic ovary syndrome with integrated traditional Chinese and western medicine. The combination of traditional Chinese and western medicine is used for the basic conditioning of the patient's body, and the western medicine composition is mainly used for To promote the ovulation function of the patient's body.
为解决上述技术问题,本发明提供的技术方案为:一种改善多囊卵巢综合征中西医结合治疗方法,所述治疗方法包括内服中药制剂和注射西药组合物,所述中药制剂用于患者机体基础调理,所述西药组合物用于促进患者机体卵巢排卵功能。In order to solve the above technical problems, the technical solution provided by the present invention is: a method for improving the treatment of polycystic ovary syndrome with integrated traditional Chinese and Western medicine, the treatment method includes oral administration of traditional Chinese medicine preparations and injections of western medicine compositions, and the traditional Chinese medicine preparations are used for the patient's body. For basic conditioning, the western medicine composition is used to promote the ovarian ovulation function of a patient's body.
进一步的,所述中药制剂包括如下重量组份的原料:白苏子3-5份、黄柏4-6份、丹参3-7份、桃仁10-14份、玄参3-5份、石斛4-6份、布狗尾5-9份、刺柄莲座蕨4-6份、女贞子8-12份、泽泻4-6份、胡黄连5-9份、车前草10-14份、虎杖5-9份、珍珠草10-14份。Further, the traditional Chinese medicine preparation includes the following raw materials by weight: 3-5 parts of perilla seed, 4-6 parts of Cortex Phellodendri, 3-7 parts of Salvia miltiorrhiza, 10-14 parts of peach kernel, 3-5 parts of Scrophulariaceae, 4 parts of Dendrobium -6 parts, 5-9 parts of dogtail, 4-6 parts of rosette fern, 8-12 parts of Ligustrum lucidum, 4-6 parts of Alisma, 5-9 parts of berberine, 10-14 parts of plantain , 5-9 parts of knotweed, 10-14 parts of pearl grass.
进一步的,所述中药制剂的制备方法包括如下步骤:Further, the preparation method of the Chinese medicine preparation comprises the following steps:
1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;
2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;
3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.
进一步的,所述西药组合物包括含PCSK9抑制剂的生理盐水注射液。Further, the western medicine composition includes physiological saline injection containing PCSK9 inhibitor.
进一步的,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为1-8mg/Kg。Further, Alirocumab is selected as the PCSK9 inhibitor, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 1-8 mg/Kg.
进一步的,所述西药组合物注射10-30分钟内内服中药制剂。。Further, the traditional Chinese medicine preparation is taken orally within 10-30 minutes of injection of the western medicine composition. .
本发明具有如下优点:本发明解决了目前多囊卵巢综合征的常规治疗只能对症治疗以及现有治疗药物带来副作用的问题;而中西医学结合治疗方式,中药制剂主要用于患者机体基础调理,西药组合物主要用于促进患者机体卵巢排卵功能,相辅相成,不仅减少药物副作用,而且快速促排改善患者体质。本发明中通过各中药原料的合理配比,并利用各组分间的相互作用,其对多囊卵巢综合征患者的疗效好,其突出疗效表现在于能恢复患者的自主排卵月经周期,降低其高雄性激素及改善痤疮体征,具有安全性高且对人体的副作用小,减少危险性;本发明的西药组合物中经PCSK9抑制剂治疗,会使得低密度脂蛋白胆固醇下降,肝脏和卵巢中的脂滴含量下降,睾酮下降,卵巢形态有所改善,囊状卵泡减少,闭锁卵泡减少;卵巢排卵功能也有所改善,卵子质量提高。本发明的中西医结合治疗方式,在西药促排的基础上,快速改善患者内在体质,然后通过中药制剂维护内环境稳定,减少药物带来副作用,在多囊卵巢综合征的治疗具有极好的疗效。The present invention has the following advantages: the present invention solves the problem that the current conventional treatment of polycystic ovary syndrome can only be symptomatic treatment and the side effects caused by existing therapeutic drugs; while the combination of Chinese and Western medicine is the treatment method, and the traditional Chinese medicine preparation is mainly used for the basic conditioning of the patient's body The western medicine composition is mainly used to promote the ovarian ovulation function of the patient's body, complement each other, not only reduce the side effects of the medicine, but also quickly stimulate ovulation and improve the patient's physical fitness. In the present invention, through the rational proportioning of each Chinese medicine raw material and the interaction between each component, it has a good curative effect on patients with polycystic ovary syndrome, and its outstanding curative effect is that it can restore the patient's spontaneous ovulation menstrual cycle, reduce its High androgen and improvement of acne signs, high safety and small side effects on the human body, reducing risk; the western medicine composition of the present invention is treated with PCSK9 inhibitors, which will reduce low-density lipoprotein cholesterol, and lipids in the liver and ovary Droplet content decreased, testosterone decreased, ovarian shape improved, cystic follicles decreased, and atretic follicles decreased; ovarian ovulation function also improved, and egg quality improved. The integrated traditional Chinese and western medicine treatment method of the present invention, on the basis of promoting excretion of western medicine, quickly improves the patient's internal constitution, and then maintains the stability of the internal environment through traditional Chinese medicine preparations, reduces the side effects of the medicine, and has an excellent effect in the treatment of polycystic ovary syndrome. curative effect.
具体实施方式Detailed ways
下面结合实施例对本发明做进一步的详细说明。The present invention will be further described in detail below in conjunction with the examples.
一种改善多囊卵巢综合征中西医结合治疗方法,所述治疗方法包括内服中药制剂和注射西药组合物,所述中药制剂用于患者机体基础调理,所述西药组合物用于促进患者机体卵巢排卵功能。A treatment method for improving polycystic ovary syndrome with integrated traditional Chinese and Western medicine, said treatment method comprising oral administration of traditional Chinese medicine preparations and injections of western medicine compositions, said Chinese medicine preparations are used for the basic conditioning of the patient's body, and said western medicine compositions are used to promote the development of the patient's body's ovarian Ovulation function.
实施例1Example 1
所述中药制剂包括如下重量组份的原料:白苏子3份、黄柏4份、丹参3份、桃仁10份、玄参3份、石斛4份、布狗尾5份、刺柄莲座蕨4份、女贞子8份、泽泻4份、胡黄连5份、车前草10份、虎杖5份、珍珠草10份。The traditional Chinese medicine preparation includes the following raw materials by weight: 3 parts of perilla seed, 4 parts of Cortex Phellodendri, 3 parts of Salvia miltiorrhiza, 10 parts of peach kernel, 3 parts of Scrophulariaceae, 4 parts of dendrobium, 5 parts of dogtail cloth, 4 parts of rosette fern , 8 parts of Ligustrum lucidum, 4 parts of Alisma, 5 parts of Hu Huanglian, 10 parts of plantain, 5 parts of knotweed, and 10 parts of pearl grass.
所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:
1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;
2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;
3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.
所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为1mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 1 mg/Kg.
所述西药组合物注射10分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 10 minutes after injection of the western medicine composition.
实施例2Example 2
所述中药制剂包括如下重量组份的原料:白苏子5份、黄柏6份、丹参7份、桃仁14份、玄参5份、石斛6份、布狗尾9份、刺柄莲座蕨6份、女贞子12份、泽泻6份、胡黄连9份、车前草14份、虎杖9份、珍珠草14份。The traditional Chinese medicine preparation includes the following raw materials by weight: 5 parts of perilla seed, 6 parts of Cortex Phellodendri, 7 parts of Salvia miltiorrhiza, 14 parts of peach kernel, 5 parts of Scrophulariaceae, 6 parts of dendrobium, 9 parts of dogtail, 6 parts of rosette fern 12 parts of Ligustrum lucidum, 6 parts of Alisma, 9 parts of Hu Huanglian, 14 parts of plantain, 9 parts of knotweed, and 14 parts of pearl grass.
所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:
1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;
2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;
3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.
所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为8mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 8 mg/Kg.
所述西药组合物注射30分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 30 minutes after injection of the western medicine composition.
实施例3Example 3
所述中药制剂包括如下重量组份的原料:白苏子4份、黄柏5份、丹参5份、桃仁12份、玄参4份、石斛5份、布狗尾7份、刺柄莲座蕨5份、女贞子10份、泽泻5份、胡黄连7份、车前草12份、虎杖7份、珍珠草12份。The traditional Chinese medicine preparation includes the following raw materials by weight: 4 parts of perilla seed, 5 parts of Cortex Phellodendri, 5 parts of Salvia miltiorrhiza, 12 parts of peach kernel, 4 parts of Scrophulariaceae, 5 parts of dendrobium, 7 parts of dogtail cloth, 5 parts of rosette fern 10 parts of Ligustrum lucidum, 5 parts of Alisma, 7 parts of Hu Huanglian, 12 parts of plantain, 7 parts of Polygonum cuspidatum, and 12 parts of pearl grass.
所述中药制剂的制备方法包括如下步骤:The preparation method of described Chinese medicine preparation comprises the steps:
1)、取洗净的中药原料按照足量份数均匀混合,采用乙醇水溶液回流提取两次,第一次用8倍量70%乙醇回流2小时、过滤,第二次用6倍量70%乙醇回流1.5小时、过滤;合并回流提取液,浓缩,得醇提取液;1) Take the washed raw materials of traditional Chinese medicine and mix them uniformly according to sufficient parts, and use ethanol aqueous solution to reflux for extraction twice, for the first time use 8 times the amount of 70% ethanol to reflux for 2 hours, filter, and for the second time use 6 times the amount of 70% ethanol Ethanol was refluxed for 1.5 hours, filtered; the refluxed extracts were combined and concentrated to obtain an alcohol extract;
2)、将步骤1中回流提取的药渣,煎煮提取两次,第一次用12倍量纯化水煎煮2小时、过滤,第二次用8倍量纯化水煎煮1.5小时、过滤;合并提取液,浓缩,得水提取液;2), decoct the medicinal residues extracted by reflux in step 1 twice, decoct for 2 hours with 12 times the amount of purified water for the first time, filter, and decoct for 1.5 hours with 8 times the amount of purified water for the second time, filter ; Combine the extracts, concentrate, and obtain a water extract;
3)、将上述醇提取液和水提取液合并,加入体积百分比计为90%的乙醇水溶液,静置沉淀,过滤,浓缩上清液得到清膏,制得冲服的中药制剂。3) Combine the above alcohol extract and water extract, add 90% ethanol aqueous solution by volume, let stand for precipitation, filter, concentrate the supernatant to obtain a clear ointment, and prepare a Chinese medicine preparation for oral administration.
所述西药组合物包括含PCSK9抑制剂的生理盐水注射液,所述PCSK9抑制剂选用Alirocumab,所述生理盐水注射液的注射剂量根据受体重量而定,为4mg/Kg。The western medicine composition includes a physiological saline injection containing a PCSK9 inhibitor, and the PCSK9 inhibitor is selected from Alirocumab, and the injection dose of the physiological saline injection is determined according to the weight of the recipient, and is 4 mg/Kg.
所述西药组合物注射20分钟内内服中药制剂。The traditional Chinese medicine preparation is taken orally within 20 minutes after injection of the western medicine composition.
白苏子:性味辛,温,无毒,功能主治下气,消痰,润肺,宽肠。治咳逆,痰喘,气滞便秘;Fructus Perillae: pungent in nature and flavor, warm, non-toxic, functions mainly for lowering qi, reducing phlegm, moistening the lungs, and widening the intestines. Cure cough, phlegm and asthma, qi stagnation and constipation;
黄柏:性味苦,寒,归肾、膀胱、大肠经;功能清热燥湿,泻火解毒,止血;Phellodendron Phellodendri: bitter in nature and flavor, cold, returns to kidney, bladder, large intestine meridian; function of clearing away heat and dampness, purging fire and detoxifying, hemostasis;
丹参:性味苦,微寒,归心、肝经;功能祛瘀止痛,活血通经,养心除烦,凉血消痈;Radix Salviae Miltiorrhizae: bitter in nature and flavor, be slightly cold, return heart, Liver Channel; Function dispelling blood stasis to relieve pain, promoting blood circulation to stimulate menstrual flow, nourishing the heart and relieving restlessness, cooling blood and eliminating carbuncle;
桃仁:性味苦、甘,平,归心、肝、大肠经;功能活血祛瘀、润肠通便;Peach kernel: bitter in nature and flavor, sweet, flat, heart-guiding, liver, and large intestine meridian; function of promoting blood circulation and removing blood stasis, moistening intestines and laxative;
玄参:性味甘,苦,咸,微寒,归肺、胃、肾经;功能清热凉血,滋阴泻火解毒;Radix Scrophulariae: sweet in nature and flavor, bitter, salty, slightly cold, returns to lung, stomach, kidney meridians; function of clearing heat and cooling blood, nourishing yin, purging fire and detoxifying;
石斛:性味甘,微寒,归胃、肾经;功能滋阴清热,益胃生津;Dendrobium: sweet in nature and flavor, slightly cold, returns to the stomach and kidney meridians; function nourishes yin and clears away heat, nourishes the stomach and promotes body fluid;
布狗尾:性味淡,凉。功能主治清热化痰,凉血止血,杀虫,用于感冒,咳嗽,疟疾,血丝虫病,小儿疳积,吐血,咯血,尿血;Cloth dog tail: light taste, cool. Functions and indications Clearing away heat and resolving phlegm, cooling blood to stop bleeding, killing parasites, used for colds, coughs, malaria, blood filariasis, malnutrition in children, vomiting blood, hemoptysis, hematuria;
刺柄莲座蕨:性味淡,涩,性凉,功能主治清热利湿;痰止咳;解毒消肿,主泄泻;痢疾;肺热咳嗽;瘰疬;痄腮;痈疖;骨折;毒蛇咬伤;Rosaceae spinosa: mild in taste, astringent, cool in nature, functions mainly for clearing heat and promoting dampness; phlegm and cough; detoxification and swelling, controlling diarrhea; dysentery; cough due to lung heat; scrofula; mumps; carbuncle furuncle; bone fracture; venomous snake bite hurt;
女贞子:性味甘,苦,凉,归肝、肾经;功能滋补肝肾,乌须明目;Ligustrum lucidum: sweet in nature and flavor, bitter, cool, returns to the liver and kidney meridians; function nourishes the liver and kidney, black hair improves eyesight;
泽泻:性味甘、寒,归肾、膀胱经;功能利水渗湿,泄热;Alisma: sweet and cold in nature and flavor, returns to the kidney and bladder meridian; functions in diuresis and dampness expelling, expels heat;
胡黄连:性味苦,寒,归肝、胃、大肠经;功能清湿热,退虚热,除疳热;Coptis chinensis: bitter in nature and flavor, cold, returns to liver, stomach, large intestine meridian; function of clearing away damp-heat, reducing asthenia-heat, removing malnutrition-heat;
车前草:性味甘寒,归肾、肝、肺经;功能利尿、清热、明目、祛痰;Plantain: sweet and cold in nature and flavor, returns to the kidney, liver, and lung meridians; functions diuresis, clearing away heat, improving eyesight, and eliminating phlegm;
虎杖:性味微苦,微寒,归肺、肝、胆经;功能清热解毒,利湿退黄,散瘀止痛,化痰止咳;Polygonum cuspidatum: slightly bitter in nature and flavor, slightly cold, returns to the lung, liver, and gallbladder meridian; function of clearing heat and detoxifying, promoting dampness and reducing jaundice, dissipating blood stasis and relieving pain, resolving phlegm and relieving cough;
珍珠草:性味苦,甘,凉,归肺、肝经;功能清热解毒,利湿退黄,明目,消积。Pearl grass: nature and flavor are bitter, sweet, cool, return lung, liver meridian; function heat-clearing and toxic substances removing, promoting dampness to reduce jaundice, improving eyesight, eliminating stagnation.
经实验对比,本发明中的治疗方式可以对多囊卵巢综合征的治疗具有极好的疗效。Through experimental comparison, the treatment mode in the present invention can have excellent curative effect on the treatment of polycystic ovary syndrome.
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。Although the present invention has been described in detail with general descriptions and specific embodiments above, it is obvious to those skilled in the art that some modifications or improvements can be made on the basis of the present invention. Therefore, the modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the protection scope of the present invention.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910680778.4A CN110237190A (en) | 2019-07-26 | 2019-07-26 | A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910680778.4A CN110237190A (en) | 2019-07-26 | 2019-07-26 | A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110237190A true CN110237190A (en) | 2019-09-17 |
Family
ID=67893608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910680778.4A Pending CN110237190A (en) | 2019-07-26 | 2019-07-26 | A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110237190A (en) |
-
2019
- 2019-07-26 CN CN201910680778.4A patent/CN110237190A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
| CN104547961B (en) | A kind of Chinese medicine composition for treating gall stone | |
| CN103611021B (en) | Be used for the treatment of medicine of Vesica sus domestica inflammation and preparation method thereof | |
| CN105596861A (en) | Pill used for treating adverse reaction after CT enhancement scanning and preparation method | |
| CN102805834B (en) | Drug for curing gastritis and preparation method thereof | |
| CN101890081A (en) | Formula of Chinese medicament for treating female infertility and processing method of Chinese medicament | |
| CN104940718A (en) | Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof | |
| CN110237190A (en) | A Method for Improving the Treatment of Polycystic Ovarian Syndrome with Integrated Traditional Chinese and Western Medicine | |
| CN100374136C (en) | A deer antler capsule | |
| CN104771637A (en) | Cholagogic and lithagogue agent for treating gallstone and preparation method thereof | |
| CN103405554B (en) | A drug used to cleanse the bowel before abdominal surgery | |
| CN108186802A (en) | A kind of Chinese medicine composition for preventing or treating leukoplakia vulvae and preparation method thereof | |
| CN105727069A (en) | Medicinal composition for treating chronic cholecystitis and preparation method for medicinal composition | |
| CN103417772B (en) | Oral bowel preparation medicine before gynecological operation | |
| CN103417843B (en) | A preparation method for Qingchang Granules before gynecological surgery | |
| CN119548605A (en) | A Chinese medicine composition for treating fractures and its application | |
| CN105267895A (en) | Medicine for treating bovine postpartum blood stasis type placenta retension and preparing method thereof | |
| CN111467413A (en) | A kind of traditional Chinese medicine composition for treating postpartum constipation and its preparation method and application | |
| CN103405555B (en) | A preparation method of Qingchang Granules for urological laparoscopic surgery | |
| CN120037339A (en) | A Chinese medicine formula for treating cough caused by mycoplasma pneumonia infection | |
| CN117482175A (en) | A kind of traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN104367862A (en) | Traditional Chinese medicinal composition for treating urethral calculus | |
| CN118045154A (en) | A Chinese medicine composition for treating cholelithiasis and its preparation method and application | |
| CN117731741A (en) | A traditional Chinese medicine composition for treating liver fibrosis and early cirrhosis and its preparation method | |
| CN104225506A (en) | Medicinal preparation for treating thrombocytopenia after chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |